 MINNEAPOLIS, MN ACCESSWIRE June 28, 2021 Celcuity Inc. Nasdaq:CELC, a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced that it has commenced an underwritten public offering of shares of its common stock. As part of the offering, Celcuity expects to grant the underwriters a 30-day option to purchase up to an additional 15 of the shares of common stock offered in the public offering. 